Safety And Pharmacokinetics Of MM-302, A HER2-targeted Antibody–liposomal Doxorubicin Conjugate, In Patients With Advanced HER2-positive Breast Cancer: A Phase 1 Dose-escalation Study
Pamela Munster, Ian E. Krop, Patricia LoRusso, Cynthia Ma, Barry A. Siegel, Anthony F. Shields, István Molnár, Thomas J. Wickham, Joseph Reynolds, Karen Campbell, Bart S. Hendriks, Bambang S. Adiwijaya, Elena Geretti, Victor Moyo, Kathy D. Miller
Twitter
Facebook
LinkedIn
Email